JP2019516754A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019516754A5 JP2019516754A5 JP2018561512A JP2018561512A JP2019516754A5 JP 2019516754 A5 JP2019516754 A5 JP 2019516754A5 JP 2018561512 A JP2018561512 A JP 2018561512A JP 2018561512 A JP2018561512 A JP 2018561512A JP 2019516754 A5 JP2019516754 A5 JP 2019516754A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- cells
- population
- pluripotent cells
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022110028A JP7622006B2 (ja) | 2016-05-25 | 2022-07-07 | 癌を処置するための方法及び組成物 |
| JP2024168499A JP7880390B2 (ja) | 2016-05-25 | 2024-09-27 | 癌を処置するための方法及び組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16305607.0 | 2016-05-25 | ||
| EP16305607 | 2016-05-25 | ||
| PCT/EP2017/062604 WO2017202949A1 (en) | 2016-05-25 | 2017-05-24 | Methods and compositions for treating cancers |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022110028A Division JP7622006B2 (ja) | 2016-05-25 | 2022-07-07 | 癌を処置するための方法及び組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019516754A JP2019516754A (ja) | 2019-06-20 |
| JP2019516754A5 true JP2019516754A5 (enExample) | 2020-07-09 |
| JP7563872B2 JP7563872B2 (ja) | 2024-10-08 |
Family
ID=56131478
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018561512A Active JP7563872B2 (ja) | 2016-05-25 | 2017-05-24 | 癌を処置するための方法及び組成物 |
| JP2022110028A Active JP7622006B2 (ja) | 2016-05-25 | 2022-07-07 | 癌を処置するための方法及び組成物 |
| JP2024168499A Active JP7880390B2 (ja) | 2016-05-25 | 2024-09-27 | 癌を処置するための方法及び組成物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022110028A Active JP7622006B2 (ja) | 2016-05-25 | 2022-07-07 | 癌を処置するための方法及び組成物 |
| JP2024168499A Active JP7880390B2 (ja) | 2016-05-25 | 2024-09-27 | 癌を処置するための方法及び組成物 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11458194B2 (enExample) |
| EP (1) | EP3463433A1 (enExample) |
| JP (3) | JP7563872B2 (enExample) |
| KR (3) | KR20190032295A (enExample) |
| CN (2) | CN109689089A (enExample) |
| AU (2) | AU2017270234B2 (enExample) |
| BR (1) | BR112018074192A8 (enExample) |
| CA (1) | CA3025057A1 (enExample) |
| IL (2) | IL305882B2 (enExample) |
| RU (1) | RU2741786C2 (enExample) |
| WO (1) | WO2017202949A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| CN105939767B (zh) | 2014-01-08 | 2018-04-06 | 弗洛设计声能学公司 | 具有双声电泳腔的声电泳装置 |
| US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
| US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
| US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
| EP4650005A3 (en) | 2016-07-15 | 2026-01-28 | Viracta Subsidiary, Inc. | Histone deacetylase inhibitors for use in immunotherapy |
| IL314506A (en) | 2017-11-24 | 2024-09-01 | Inst Nat Sante Rech Med | Methods and preparations for the treatment of cancer |
| CN114900773A (zh) | 2017-12-14 | 2022-08-12 | 弗洛设计声能学公司 | 声泳系统及其操作方法、控制声换能器及声学系统的方法 |
| CN111936161B (zh) * | 2018-01-02 | 2024-06-18 | 克洛里斯生物科学有限公司 | 作为癌症的预防性和诊疗性治疗的ipsc基疫苗 |
| WO2019140296A1 (en) * | 2018-01-12 | 2019-07-18 | Viracta Therapeutics, Inc. | Epigenetic modifiers for use in cellular immunotherapy |
| US12599662B2 (en) | 2018-08-06 | 2026-04-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treating cancers |
| US20220154219A1 (en) * | 2019-03-22 | 2022-05-19 | The Johns Hopkins University | Gene delivery particles to induce tumor-derived antigen presenting cells |
| US20220313734A1 (en) * | 2019-05-09 | 2022-10-06 | Figene, Llc | Fibroblast generated patient-specific vaccines |
| WO2020232373A1 (en) * | 2019-05-15 | 2020-11-19 | Board Of Regents, The University Of Texas System | Crispr methods for treating cancers |
| JP7352937B2 (ja) * | 2019-07-19 | 2023-09-29 | 公立大学法人福島県立医科大学 | 乳癌のサブタイプを鑑別又は分類するための鑑別マーカー遺伝子セット、方法およびキット |
| CN111358777A (zh) * | 2020-02-24 | 2020-07-03 | 军事科学院军事医学研究院环境医学与作业医学研究所 | 一种提高外周血单个核细胞线粒体功能的方法和应用 |
| GB202006254D0 (en) | 2020-04-28 | 2020-06-10 | Institute Of Cancer Res | Anti-cancer vaccines and related therapy |
| US20230174636A1 (en) * | 2020-05-12 | 2023-06-08 | Rush University Medical Center | Compositions and methods for treating cancer |
| CN112603995B (zh) * | 2020-12-30 | 2022-03-18 | 四川省肿瘤医院 | 靶向CAFs的肿瘤细胞疫苗、其制备方法及其应用 |
| WO2022208040A1 (en) * | 2021-03-31 | 2022-10-06 | Celleron Therapeutics Limited | Vaccine adjuvant |
| JP7898763B2 (ja) * | 2021-04-05 | 2026-08-03 | ピノットバイオ インコーポレイテッド | ４’－チオ－５－アザ－２’－デオキシシチジンおよびベネトクラクスの併用療法 |
| WO2023159124A2 (en) * | 2022-02-17 | 2023-08-24 | Memorial Sloan-Kettering Cancer Center | Methods for overcoming tazemetostat-resistance in cancer patients |
| CN115494237B (zh) * | 2022-09-19 | 2025-06-24 | 浙江省人民医院 | Rps6ka2在制备卵巢癌诊断试剂和治疗药物中的应用 |
| WO2024178965A1 (en) * | 2023-02-27 | 2024-09-06 | Wuhan University | Modulation of pd-1 signaling for treatment of diseases |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL8200523A (nl) | 1982-02-11 | 1983-09-01 | Univ Leiden | Werkwijze voor het in vitro transformeren van planteprotoplasten met plasmide-dna. |
| US4806476A (en) | 1983-09-08 | 1989-02-21 | Lovelace Medical Foundation | Efficient cell fusion process |
| US5071773A (en) | 1986-10-24 | 1991-12-10 | The Salk Institute For Biological Studies | Hormone receptor-related bioassays |
| WO1990001541A1 (en) | 1988-08-04 | 1990-02-22 | Amrad Corporation Limited | In vitro propagation of embryonic stem cells |
| US5240840A (en) | 1991-04-05 | 1993-08-31 | Regents Of The University Of Michigan | Dna superfragment cloning |
| JP3314241B2 (ja) | 1992-04-06 | 2002-08-12 | ヤマハ発動機株式会社 | 自動二輪車用エンジンの排気浄化装置 |
| US5690926A (en) | 1992-10-08 | 1997-11-25 | Vanderbilt University | Pluripotential embryonic cells and methods of making same |
| US5453357A (en) | 1992-10-08 | 1995-09-26 | Vanderbilt University | Pluripotential embryonic stem cells and methods of making same |
| US5618829A (en) | 1993-01-28 | 1997-04-08 | Mitsubishi Chemical Corporation | Tyrosine kinase inhibitors and benzoylacrylamide derivatives |
| CA2167153A1 (en) | 1993-07-15 | 1995-01-26 | Caroline Joy Springer | Prodrugs of protein tyrosine kinase inhibitors |
| US5804396A (en) | 1994-10-12 | 1998-09-08 | Sugen, Inc. | Assay for agents active in proliferative disorders |
| US5914268A (en) | 1994-11-21 | 1999-06-22 | National Jewish Center For Immunology & Respiratory Medicine | Embryonic cell populations and methods to isolate such populations |
| US5843780A (en) | 1995-01-20 | 1998-12-01 | Wisconsin Alumni Research Foundation | Primate embryonic stem cells |
| US5639757A (en) | 1995-05-23 | 1997-06-17 | Pfizer Inc. | 4-aminopyrrolo[2,3-d]pyrimidines as tyrosine kinase inhibitors |
| US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US5855887A (en) | 1995-07-25 | 1999-01-05 | The Regents Of The University Of California | Blockade of lymphocyte down-regulation associated with CTLA-4 signaling |
| US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| CN100503580C (zh) | 1996-04-12 | 2009-06-24 | 沃尼尔·朗伯公司 | 酪氨酸激酶的不可逆抑制剂 |
| US6207157B1 (en) | 1996-04-23 | 2001-03-27 | The United States Of America As Represented By The Department Of Health And Human Services | Conjugate vaccine for nontypeable Haemophilus influenzae |
| US6331406B1 (en) | 1997-03-31 | 2001-12-18 | The John Hopkins University School Of Medicine | Human enbryonic germ cell and methods of use |
| US6090622A (en) | 1997-03-31 | 2000-07-18 | The Johns Hopkins School Of Medicine | Human embryonic pluripotent germ cells |
| ZA986732B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
| US6100254A (en) | 1997-10-10 | 2000-08-08 | Board Of Regents, The University Of Texas System | Inhibitors of protein tyrosine kinases |
| WO1999020740A2 (en) | 1997-10-23 | 1999-04-29 | Geron Corporation | Methods and materials for the growth of primate-derived primordial stem cells |
| US6835867B1 (en) | 1998-06-24 | 2004-12-28 | Richard P. Woychik | Allelic series of genomic modifications in cells |
| US6667176B1 (en) | 2000-01-11 | 2003-12-23 | Geron Corporation | cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells |
| US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
| US6740665B1 (en) | 1999-02-10 | 2004-05-25 | Ramachandran Murali | Tyrosine kinase inhibitors and methods of using the same |
| US6245759B1 (en) | 1999-03-11 | 2001-06-12 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| WO2001000214A1 (en) | 1999-06-30 | 2001-01-04 | Merck & Co., Inc. | Src kinase inhibitor compounds |
| US6329380B1 (en) | 1999-06-30 | 2001-12-11 | Merck & Co., Inc. | SRC kinase inhibitor compounds |
| EP1206265B1 (en) | 1999-06-30 | 2003-11-12 | Merck & Co., Inc. | Src kinase inhibitor compounds |
| NZ517202A (en) | 1999-08-24 | 2004-05-28 | Medarex Inc | Human CTLA-4 antibodies and their uses |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| MXPA02002559A (es) | 1999-09-10 | 2002-07-30 | Merck & Co Inc | Inhibidores de tirosina cinasa. |
| AU778042B2 (en) | 1999-10-19 | 2004-11-11 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| US6794393B1 (en) | 1999-10-19 | 2004-09-21 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| WO2001029025A2 (en) | 1999-10-19 | 2001-04-26 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| US6313138B1 (en) | 2000-02-25 | 2001-11-06 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| US6420382B2 (en) | 2000-02-25 | 2002-07-16 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| NL1017973C2 (nl) | 2000-05-10 | 2002-11-08 | Tristem Trading Cyprus Ltd | Inrichting. |
| AU785428B2 (en) | 2000-08-30 | 2007-05-17 | Maria Biotech Co., Ltd | Human embryonic stem cells derived from frozen-thawed embryo |
| JP4183614B2 (ja) | 2001-05-31 | 2008-11-19 | 伸弥 山中 | Ｅｓ細胞特異的発現遺伝子 |
| ATE316088T1 (de) | 2001-06-22 | 2006-02-15 | Merck & Co Inc | Tyrosin-kinase inhibitoren |
| US6958340B2 (en) | 2001-08-01 | 2005-10-25 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| WO2003020276A1 (en) | 2001-08-30 | 2003-03-13 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| EP1456652A4 (en) | 2001-11-13 | 2005-11-02 | Dana Farber Cancer Inst Inc | IMMUNOCELL ACTIVATION MODULATING SUBSTANCES AND USE METHOD THEREFOR |
| ES2367430T3 (es) | 2002-12-23 | 2011-11-03 | Wyeth Llc | Anticuerpos contra pd-1 y sus usos. |
| WO2005047524A2 (en) | 2003-11-10 | 2005-05-26 | The Scripps Research Institute | Compositions and methods for inducing cell dedifferentiation |
| EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| KR101704734B1 (ko) | 2005-07-01 | 2017-02-09 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| US8278104B2 (en) | 2005-12-13 | 2012-10-02 | Kyoto University | Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2 |
| US8129187B2 (en) | 2005-12-13 | 2012-03-06 | Kyoto University | Somatic cell reprogramming by retroviral vectors encoding Oct3/4. Klf4, c-Myc and Sox2 |
| US7908091B2 (en) | 2006-03-17 | 2011-03-15 | Prometheus Laboratories Inc. | Methods of predicting and monitoring tyrosine kinase inhibitor therapy |
| CA2659021A1 (en) | 2006-07-20 | 2008-01-24 | Richard Burt | Method of using mitotically inactivated stem cells for damaged tissue repair |
| EP2091525A1 (en) | 2006-12-06 | 2009-08-26 | Sapporo Medical University | Potentiation of cellular immunity using histone deacetylase (hdac) inhibitors |
| PT2170959E (pt) | 2007-06-18 | 2014-01-07 | Merck Sharp & Dohme | Anticorpos para o receptor humano de morte programada pd-1 |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| JP5346925B2 (ja) | 2008-05-02 | 2013-11-20 | 国立大学法人京都大学 | 核初期化方法 |
| WO2010036959A2 (en) | 2008-09-26 | 2010-04-01 | Dana-Farber Cancer Institute | Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor |
| MX356367B (es) | 2008-12-09 | 2018-05-25 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t. |
| WO2010089411A2 (en) | 2009-02-09 | 2010-08-12 | Universite De La Mediterranee | Pd-1 antibodies and pd-l1 antibodies and uses thereof |
| EP2504028A4 (en) | 2009-11-24 | 2014-04-09 | Amplimmune Inc | SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2 |
| US20130022629A1 (en) | 2010-01-04 | 2013-01-24 | Sharpe Arlene H | Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof |
| US9163087B2 (en) | 2010-06-18 | 2015-10-20 | The Brigham And Women's Hospital, Inc. | Bi-specific antibodies against TIM-3 and PD-1 for immunotherapy in chronic immune conditions |
| US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
| WO2012060473A1 (en) | 2010-11-04 | 2012-05-10 | Kyoto University | Method of efficiently establishing induced pluripotent stem cells |
| US9534206B2 (en) | 2010-12-16 | 2017-01-03 | General Electric Company | Cell carrier, associated methods for making cell carrier and culturing cells using the same |
| US20130136722A1 (en) * | 2011-11-11 | 2013-05-30 | The Board Of Trustees Of The University Of Illinois | Methods of Ex Vivo Expansion of Blood Progenitor Cells, and Generation of Composite Grafts |
| US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
-
2017
- 2017-05-24 RU RU2018141200A patent/RU2741786C2/ru active
- 2017-05-24 CA CA3025057A patent/CA3025057A1/en active Pending
- 2017-05-24 BR BR112018074192A patent/BR112018074192A8/pt not_active Application Discontinuation
- 2017-05-24 KR KR1020187037459A patent/KR20190032295A/ko not_active Ceased
- 2017-05-24 AU AU2017270234A patent/AU2017270234B2/en active Active
- 2017-05-24 WO PCT/EP2017/062604 patent/WO2017202949A1/en not_active Ceased
- 2017-05-24 IL IL305882A patent/IL305882B2/en unknown
- 2017-05-24 KR KR1020227044304A patent/KR102677451B1/ko active Active
- 2017-05-24 CN CN201780045481.XA patent/CN109689089A/zh active Pending
- 2017-05-24 KR KR1020247020115A patent/KR20240103039A/ko active Pending
- 2017-05-24 IL IL263224A patent/IL263224B2/en unknown
- 2017-05-24 JP JP2018561512A patent/JP7563872B2/ja active Active
- 2017-05-24 US US16/303,705 patent/US11458194B2/en active Active
- 2017-05-24 EP EP17726274.8A patent/EP3463433A1/en active Pending
- 2017-05-24 CN CN202211701185.XA patent/CN116376812A/zh active Pending
-
2022
- 2022-07-07 JP JP2022110028A patent/JP7622006B2/ja active Active
- 2022-07-28 US US17/815,586 patent/US20220370582A1/en active Pending
-
2024
- 2024-01-30 AU AU2024200549A patent/AU2024200549B2/en active Active
- 2024-09-27 JP JP2024168499A patent/JP7880390B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2018141200A (ru) | Способы и композиции для лечения опухолей | |
| JP2021504465A5 (enExample) | ||
| Mazzone et al. | Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacy | |
| JP5452231B2 (ja) | 化学的に修飾した正常な細胞由来の抗腫瘍ワクチン | |
| Vandenberk et al. | Exploiting the immunogenic potential of cancer cells for improved dendritic cell vaccines | |
| JP2022093564A (ja) | キメラ抗原受容体（ｃａｒ）並びにその製造及び使用方法 | |
| Schnekenburger et al. | Epigenetic alterations as a universal feature of cancer hallmarks and a promising target for personalized treatments | |
| Zhong et al. | Immunotherapy for hepatocellular carcinoma: current limits and prospects | |
| CN117731763A (zh) | 过继细胞转移与溶瘤病毒组合疗法 | |
| RU2021132734A (ru) | Химерные рецепторы антигена, нацеленные на psca | |
| Du et al. | Hypothermic microenvironment plays a key role in tumor immune subversion | |
| JP2012515213A5 (enExample) | ||
| JP2013537187A5 (enExample) | ||
| JP2018506995A5 (enExample) | ||
| JP2019512020A5 (enExample) | ||
| JP2021519087A5 (enExample) | ||
| JP2018048151A5 (enExample) | ||
| CA3200513A1 (en) | Tumor cell vaccines | |
| WO2016020434A1 (en) | Method for expanding immune cells | |
| CN105873639A (zh) | 自体肿瘤疫苗和方法 | |
| Obertopp et al. | Local single-dose radiation improves adoptive cell therapy with tumor-infiltrating lymphocytes | |
| JP2020535832A5 (enExample) | ||
| Nejad et al. | Antitumor immunity enhancement through Newcastle viral oncolysate in mice model: A promising method to treat tumors | |
| Har-Noy et al. | Allogeneic CD3/CD28 cross-linked Th1 memory cells provide potent adjuvant effects for active immunotherapy of leukemia/lymphoma | |
| Teitz-Tennenbaum et al. | Dendritic cells pulsed with keyhole limpet hemocyanin and cryopreserved maintain anti-tumor activity in a murine melanoma model |